Frédéric Perros Selected Research

Pulmonary Veno-Occlusive Disease (Veno Occlusive Disease, Pulmonary)

1/2021	Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C.
10/2020	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno-occlusive disease.
1/2018	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.
4/2016	Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model".
12/2015	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease.
9/2015	Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Frédéric Perros Research Topics

Disease

22	Pulmonary Hypertension 01/2022 - 07/2011
22	Pulmonary Arterial Hypertension 01/2022 - 02/2005
10	Hypoxia (Hypoxemia) 01/2022 - 01/2014
10	Familial Primary Pulmonary Hypertension 01/2020 - 11/2007
6	Inflammation (Inflammations) 12/2021 - 09/2011
6	Pulmonary Veno-Occlusive Disease (Veno Occlusive Disease, Pulmonary) 01/2021 - 09/2015
6	Vascular Remodeling 01/2018 - 11/2007
3	Heart Failure 07/2021 - 05/2012
3	Hypertrophy 02/2021 - 06/2014
3	Rare Diseases (Rare Disease) 08/2018 - 09/2015
3	Right Ventricular Hypertrophy 01/2018 - 01/2013
2	Fibrosis (Cirrhosis) 11/2021 - 06/2014
2	Cystic Fibrosis (Mucoviscidosis) 11/2021 - 01/2014
2	Vascular Diseases (Vascular Disease) 12/2016 - 11/2016
2	Autoimmune Diseases (Autoimmune Disease) 06/2013 - 10/2012
2	Connective Tissue Diseases (Connective Tissue Disease) 01/2012 - 06/2007
1	Pulmonary Embolism 01/2022
1	Heart Diseases (Heart Disease) 01/2022
1	Genetic Predisposition to Disease (Genetic Predisposition) 12/2021
1	Anemia 07/2021
1	Iron Deficiencies 01/2021
1	Drug-Related Side Effects and Adverse Reactions 01/2021
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2020
1	Genomic Instability 07/2019
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2019
1	Pneumonia (Pneumonitis) 01/2016
1	Neoplasms (Cancer) 01/2016
1	Cardiomegaly (Heart Hypertrophy) 01/2016
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2014
1	Edema (Dropsy) 07/2013
1	Ascites 07/2013

Drug/Important Bio-Agent (IBA)

13	MonocrotalineIBA 11/2021 - 09/2011
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 02/2005
3	Transcription Factors (Transcription Factor)IBA 01/2022 - 11/2016
3	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2021 - 09/2015
3	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 10/2020 - 11/2016
3	Type II Bone Morphogenetic Protein Receptors (Bone Morphogenetic Protein Receptor Type II)IBA 01/2018 - 10/2015
2	Messenger RNA (mRNA)IBA 11/2021 - 01/2014
2	IronIBA 07/2021 - 01/2021
2	LigandsIBA 02/2021 - 11/2007
2	Carbon MonoxideIBA 01/2021 - 01/2020
2	Semaxinib (SU5416)IBA 01/2021 - 10/2020
2	Serotonin (5 Hydroxytryptamine)IBA 10/2020 - 02/2005
2	DNA (Deoxyribonucleic Acid)IBA 07/2019 - 12/2016
2	potassium channel subfamily K member 3IBA 01/2019 - 04/2016
2	Phosphotransferases (Kinase)IBA 01/2018 - 10/2012
2	Interleukin-6 (Interleukin 6)IBA 08/2014 - 06/2014
2	AutoantibodiesIBA 06/2013 - 02/2012
1	Peptidylprolyl Isomerase (Prolyl Isomerase)IBA 01/2022
1	jugloneIBA 01/2022
1	Dobutamine FDA LinkGeneric 01/2022
1	Biological ProductsIBA 12/2021
1	CollagenIBA 12/2021
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2021
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 11/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 02/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	Leflunomide (Arava)FDA LinkGeneric 01/2021
1	EnbucrilateIBA 11/2020
1	cadherin 5IBA 10/2020
1	Vitamin D FDA LinkGeneric 10/2020
1	SurvivinIBA 10/2020
1	Trichloroethylene (Trichloroethene)IBA 10/2020
1	PotassiumIBA 10/2020
1	LipidsIBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	15-hydroxy-5,8,11,13-eicosatetraenoic acidIBA 01/2020
1	CholesterolIBA 01/2020
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2020
1	AcidsIBA 01/2020
1	hemoglobin DIBA 01/2020
1	Pharmaceutical PreparationsIBA 08/2018
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2018
1	Sirtuin 1IBA 01/2018
1	Glutamic Acid (Glutamate)FDA Link 01/2018
1	Eukaryotic Initiation Factor-2 (EIF 2)IBA 01/2018
1	N-Methylaspartate (NMDA)IBA 01/2018
1	CalciumIBA 11/2016
1	hydralazine 4-anisaldehyde hydrazoneIBA 11/2016
1	ProteomeIBA 10/2016
1	MicroRNAs (MicroRNA)IBA 01/2016
1	SolventsIBA 12/2015
1	Potassium Channels (Potassium Channel)IBA 10/2015
1	Metoprolol (Toprol-XL)FDA LinkGeneric 02/2015
1	Nebivolol FDA Link 02/2015
1	Alkylating AgentsIBA 02/2015
1	AlarminsIBA 08/2014
1	Interleukin-33IBA 08/2014
1	InterleukinsIBA 08/2014
1	Acetylcysteine (Siran)FDA LinkGeneric 06/2014
1	DiureticsIBA 07/2013
1	Gonadal Steroid Hormones (Sex Hormones)IBA 06/2013
1	Suramin (Suramin Sodium)IBA 01/2013
1	Epidermal Growth Factor (EGF)IBA 10/2012
1	Imatinib Mesylate (Gleevec)FDA Link 10/2012
1	Gefitinib (Iressa)FDA Link 10/2012

Therapy/Procedure

9	Therapeutics 12/2021 - 06/2007
2	Drug Therapy (Chemotherapy) 01/2019 - 02/2015
2	Transplantation 10/2012 - 06/2012
1	Hematopoietic Stem Cell Transplantation 01/2019